ClinicalTrials.gg
CompletedNCT03173547Updated Aug 10, 2021Results posted

A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris

A Phase 2 interventional study of 146-9251 cream and Vehicle cream in Ichthyosis Vulgaris, sponsored by Crown Laboratories, Inc.. Completed at 7 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-08-10.

Sponsored by Crown Laboratories, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The objective of this study is to determine and compare the safety and efficacy of topical 146-9251 cream and vehicle cream applied twice daily for 6 weeks in subjects with moderate to severe ichthyosis vulgaris (IV).

02

Conditions studied

  • Ichthyosis Vulgaris
03

In context

Lead sponsor

Crown Laboratories, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female and is at least 12 years old at the time of enrollment.
  2. Subject has provided written /assent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide informed consent for the subject. If a subject becomes 18 years of age during the study, the subject must provide written informed consent at that time to continue study participation.
  3. Subject and parent/guardian (if applicable) are willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
  4. Subject has a clinical diagnosis of ichthyosis vulgaris involving a minimum of 5% body surface area (BSA). If the subject has IV involving over 40% BSA, the investigator must be able to identify a Treatment Area comprising distinct anatomic units that contains about 40% (excluding the scalp and mucosal areas) as detailed in Section 6.2.
  5. Subject has an Investigator's Global Assessment (IGA) score of at least three (3 = moderate) at the Baseline Visit.
  6. Subject is in good general health and free of any disease state or physical condition that might impair evaluation of IV or which, in the investigator's opinion, exposes the subject to an unacceptable risk by study participation.
  7. Females must be , surgically sterile, or use an effective method of . , Women of (WOCBP) must have with a negative urine pregnancy test (UPT) at the Baseline Visit.

Exclusion criteria

Exclusion Criteria:

    1. Subject is pregnant, lactating, or is planning to become pregnant during the study.

      1. Subject is currently enrolled in an drug or device study. 3. Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.
      1. Subject has used any topical therapy, including topical or retinoids, in the Treatment Area within 2 weeks prior to the initiation of treatment. Note: a bland emollient may be used in the Treatment Area up to 3 days prior to the initiation of treatment.
      1. Subject has used systemic corticosteroids within 4 weeks or retinoids within 24 weeks prior to the initiation of treatment.
      1. Subject has stable use of vitamin or herbal supplements for less than 2 weeks prior to the initiation of treatment.
      1. Subject has a history of sensitivity to any of the ingredients in the test articles.
      1. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
      1. Subject has a physical condition or other dermatologic disorders (e.g., atopic, seborrheic or contact dermatitis, psoriasis, tinea infections, etc.) which, in the investigator's opinion, might impair evaluation of IV, or which exposes the subject to unacceptable risk by study participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    146-9251 cream

    Topical cream to be applied two times daily to specified treatment areas for 6 weeks.

    Drug: 146-9251 cream

  • Placebo comparator
    Vehicle cream

    Topical cream to be applied two times daily to specified treatment areas for 6 weeks.

    Drug: Vehicle cream

Interventions

  • Drug146-9251 cream

    146-9251 cream contains an active drug and is applied topically.

  • DrugVehicle cream

    Vehicle cream does not contain an active drug and is applied topically.

06

What researchers measure

Primary outcomes

  1. Treatment Success

    Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks. The IGA score is a static evaluation of the overall or "average" degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area. IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Day 43 (6 weeks)

Other outcomes

  1. Adverse Events (AEs)

    AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.

    Time frame: Day 0 through study completion, average 6 weeks, Day 43.

07

Results

Posted Jul 14, 2021

Participant flow

Participant flow — Overall Study
Milestone146-9251 CreamVehicle Cream
Started4040
Completed3638
Not completed42
Withdrew: Adverse event20
Withdrew: Withdrawal by subject22

Outcome measures

PrimaryTreatment Success

Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks. The IGA score is a static evaluation of the overall or "average" degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area. IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Time frame:
Day 43 (6 weeks)
Reported as:
Count of participants · Participants
Treatment Success
Participants146-9251 CreamVehicle Cream
Treatment Success2128
Other pre-specifiedAdverse Events (AEs)

AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.

Time frame:
Day 0 through study completion, average 6 weeks, Day 43.
Reported as:
Count of participants · Participants
Adverse Events (AEs)
Participants146-9251 CreamVehicle Cream
Number of Subjects with any AE914
Number of Subjects without an AE3126

Adverse events

Collected over AEs were collected from study day 1 to end of study (week 6).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
146-9251 Cream0/40 (0%)0/40 (0%)0/40 (0%)
Vehicle Cream0/40 (0%)0/40 (0%)5/40 (12.5%)
Most frequent other events
Most frequent other events
Event146-9251 CreamVehicle Cream
NasopharyngitisInfections and infestations0/405/40

Baseline characteristics

Intent to treat (ITT) population defined as subjects who applied at least one dose of the assigned test article.

Age, Continuous
Age, Continuous(years)146-9251 CreamVehicle CreamTotal
Mean54.8 ± 19.4151.4 ± 17.4253.1 ± 18.41
Sex: Female, Male
Sex: Female, Male(Participants)146-9251 CreamVehicle CreamTotal
Female191231
Male212849
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)146-9251 CreamVehicle CreamTotal
Hispanic or Latino336
Not Hispanic or Latino373774
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)146-9251 CreamVehicle CreamTotal
American Indian or Alaska Native000
Asian347
Native Hawaiian or Other Pacific Islander000
Black or African American257
White333063
More than one race112
Unknown or Not Reported101
Investigator's Global Assessment (IGA) Score
Investigator's Global Assessment (IGA) Score(Participants)146-9251 CreamVehicle CreamTotal
3-Moderate303161
4-Severe10919
08

Study locations

7 sites
  • Crown investigative site 01
    San Diego, California 92123, United States
  • Crown Investigative site 07
    Plainfield, Indiana 46168, United States
  • Crown Investigative site 08
    Metairie, Louisiana 70006, United States
  • Crown Investigative site 02
    Fridley, Minnesota 55432, United States
  • Crown Investigative site 04
    Columbia, Missouri 65212, United States
  • Crown Investigative Site 05
    Albuquerque, New Mexico 87106, United States
  • Crown Investigative site 06
    High Point, North Carolina 27262, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Apr 2019, 24 months.

Results were first posted in Jul 2021, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2017
First posted
Jun 2, 2017
StartActual
Apr 25, 2017
Primary completionActual
Apr 30, 2019
CompletionActual
Jul 31, 2019
Results first posted
Jul 14, 2021
Last update
Aug 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03173547
Responsible party
Sponsor
First posted
Jun 2, 2017
Start date
Apr 25, 2017
Primary completion
Apr 30, 2019
Completion
Jul 31, 2019
Results posted
Jul 14, 2021
Last update
Aug 10, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion